This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports the development of IN-002, an inhaled monoclonal antibody therapy for respiratory syncytial virus (RSV) infections. Specifically, the $1,024,926 in funding will be used by the awardee, Inhalon Biopharma, Inc., to complete non-clinical activities associated with a planned Phase 1 clinical study of IN-002. This includes processing clinical trial biospecimens to determine drug levels, performing pharmacokinetic modeling, and preparing the clinical study report. The overall goal is to advance IN-002 towards a Phase 2 efficacy study to evaluate this inhaled antibody treatment for RSV, which is a leading cause of viral hospitalization and death in infants and young children. The grant award will further support Inhalon's ongoing efforts to develop a platform of inhaled monoclonal antibody therapies that can be self-administered at home to target respiratory infections directly in the airways.
Generated 3/4/25, 5:41 AM